外科理论与实践

外科理论与实践 >

2022 , Vol. 27 >Issue 01: 83 - 86

DOI: https://doi.org/10.16139/j.1007-9610.2022.01.019

综述

奥曲肽预防胰十二指肠切除术后胰漏的研究进展

展开
  • 上海交通大学医学院附属仁济医院胆胰外科,上海 200127

收稿日期: 2021-11-10

  网络出版日期: 2022-03-17

基金资助

上海市科学技术委员会科研计划项目(19411966400)

收起

Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress

Expand
  • Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Received date: 2021-11-10

  Online published: 2022-03-17

Fold

摘要

胰十二指肠切除术后胰漏发生率居高不下,是导致术后死亡的主要原因之一。奥曲肽是一种八肽生长抑素类似物,自20世纪90年代起用于预防和治疗术后胰漏,但其有效性始终存在争议。本文拟对奥曲肽预防胰十二指肠切除术术后胰漏的研究作一综述。

关键词： 奥曲肽; 术后胰漏; 胰十二指肠切除术

本文引用格式

徐煜, 张军峰, 花荣 . 奥曲肽预防胰十二指肠切除术后胰漏的研究进展[J]. 外科理论与实践, 2022 , 27(01) : 83 -86 . DOI: 10.16139/j.1007-9610.2022.01.019

Abstract

The pancreatic leak after pancreaticoduodenectomy was one of the main causes of postoperative death, the rate of which remained high. Octreotide, an octapeptide somatostatin analogue, has been used in the prevention and treatment of postoperative pancreatic leak since the 1 990 s. However, octreotide availability was controversial until now. The study on the prevention of pancreatic leak after pancreaticoduodenectomy using octreotide was reviewed in this article.

Key words： Octreotide; Postoperative pancreatic leak; Pancreaticoduodenectomy

参考文献

[1] Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure[J]. Ann Surg, 1987, 206(3):358-365.
[2] Grace PA, Pitt HA, Tompkins RK, et al. Decreased morbidity and mortality after pancreatoduodenectomy[J]. Am J Surg, 1986, 151(1):141-149.
[3] Nassour I, Wang SC, Christie A, et al. Minimally invasive versus open pancreaticoduodenectomy: a propensity-matched study from a national cohort of patients[J]. Ann Surg, 2018, 268(1):151-157.
[4] Gleeson EM, Shaikh MF, Shewokis PA, et al. Whipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database[J]. Surgery, 2016, 160(5):1279-1287.
[5] Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies[J]. Ann Surg, 2006, 244(1):10-15.
[6] Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group(ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after[J]. Surgery, 2017, 161(3):584-591.
[7] Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition[J]. Surgery, 2005, 138(1):8-13.
[8] Maggino L, Malleo G, Bassi C, et al. Decoding grade B pancreatic fistula: a clinical and economical analysis and subclassification proposal[J]. Ann Surg, 2019, 269(6):1146-1153.
[9] Marchegiani G, Andrianello S, Salvia R, et al. Current definition of and controversial issues regarding postope-rative pancreatic fistulas[J]. Gut Liver, 2019, 13(2):149-153.
[10] 白雪莉, 沈艺南, 马涛, 等. 有关国际胰腺外科研究组术后胰瘘定义与分级系统(2016版)更新解读与探讨[J]. 中国实用外科杂志, 2017, 37(3):259-261.
[11] Akgul O, Merath K, Mehta R, et al. Postoperative pancreatic fistula following pancreaticoduodenectomy-stratification of patient risk[J]. J Gastrointest Surg, 2019, 23(9):1817-1824.
[12] Gaujoux S, Cortes A, Couvelard A, et al. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy[J]. Surgery, 2010, 148(1):15-23.
[13] Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy?[J]. Ann Surg, 2000, 232(3):419-429.
[14] Ellis RJ, Brock Hewitt D, Liu JB, et al. Preoperative risk evaluation for pancreatic fistula after pancreaticoduodenectomy[J]. J Surg Oncol, 2019, 119(8):1128-1134.
[15] Hackert T, Werner J, Buchler MW. Postoperative pancreatic fistula[J]. Surgeon, 2011, 9(4):211-217.
[16] Hosotani R, Doi R, Imamura M. Duct-to-mucosa pancreaticojejunostomy reduces the risk of pancreatic leakage after pancreatoduodenectomy[J]. World J Surg, 2002, 26(1):99-104.
[17] Adiamah A, Arif Z, Berti F, et al. The use of prophylactic somatostatin therapy following pancreaticoduodenectomy: a meta-analysis of randomised controlled trials[J]. World J Surg, 2019, 43(7):1788-1801.
[18] Tewari M, Mahendran R, Kiran T, et al. Outcome of 150 consecutive blumgart’s pancreaticojejunostomy after pancreaticoduodenectomy[J]. India J Surg Oncol, 2019, 10(1):65-71.
[19] Adachi T, Kuroki T, Kitasato A, et al. Safety and efficacy of early drain removal and triple-drug therapy to prevent pancreatic fistula after distal pancreatectomy[J]. Pancreatology, 2015, 15(4):411-416.
[20] Pessaux P, Sauvanet A, Mariette C, et al. External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy[J]. Ann Surg, 2011, 253(5):879-885.
[21] Büchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection[J]. Am J Surg, 1992, 163(1):125-130.
[22] Gurusamy KS, Koti R, Fusai G, et al. Somatostatin analogues for pancreatic surgery[J]. Cochrane Database Syst Rev, 2013, 4(6):CD008370.
[23] Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection. The importance of definitions[J]. Digest Surg, 2004, 21(1):54-59.
[24] Friess H, Beger HG, Sulkowski U, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis[J]. Br J Surg, 1995, 82(9):1270-1273.
[25] Montoris M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial[J]. Surgery, 1995, 117(1):26-31.
[26] Adachi T, Kuroki T, Kitasato A, et al. Safety and efficacy of early drain removal and triple-drug therapy to prevent pancreatic fistula after distal pancreatectomy[J]. Pancreatology, 2015, 15(4):411-416.
[27] Adachi T, Ono S, Matsushima H, et al. Efficacy of triple-drug therapy to prevent pancreatic fistulas in patients with high drain amylase levels after pancreaticoduodenectomy[J]. J Surg Res, 2019, 234:77-83.
[28] Li T, D′Cruz RT, Lim SY, et al. Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection - A systematic review & meta-analysis[J]. Pancreatology, 2020, 20(2):158-168.
[29] 张雷华, 高伟, 侯世方, 等. 应用奥曲肽预防胰十二指肠切除术后胰漏作用的研究[J]. 现代生物医学进展, 2011, 11(12):2282-2285.
[30] 孔瑞, 胡继盛, 李乐, 等. 奥曲肽对胰十二指肠切除术后胰瘘影响的前瞻性研究[J]. 中华外科杂志, 2016, 54(1):21-24.
[31] El Nakeeb A, Elgawalby A, Ali M, et al. Efficacy of octreotide in the prevention of complications after pancreaticoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: a prospective randomized trial[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(1):59-63.
[32] You DD, Paik KY, Park IY, et al. Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy[J]. Asian J Surg, 2019, 42(2):458-463.
[33] Garg PK, Sharma J, Jakhetiya A, et al. The Role of Prophylactic octreotide following pancreaticoduodenectomy to prevent postoperative pancreatic fistula: a meta-analysis of the randomized controlled trials[J]. Surg J, 2018, 4(4):e182-e187.
[34] 张鼎, 侍书成, 高运, 等. 奥曲肽预防胰腺切除术后胰瘘及相关并发症的Meta分析[J]. 中华肝胆外科杂志, 2018, 24(6):411-416.
Options
文章导航

/

〈 〉